 Anticarcinogenic Agents
"Anticarcinogenic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved.
| Descriptor ID |
D016588
|
| MeSH Number(s) |
D27.505.696.706.018 D27.505.954.248.125 D27.720.799.018
|
| Concept/Terms |
Anticarcinogenic Agents- Anticarcinogenic Agents
- Agents, Anticarcinogenic
- Anti-Carcinogenic Drugs
- Anti Carcinogenic Drugs
- Drugs, Anti-Carcinogenic
- Anticarcinogens
- Anti-Carcinogenic Agents
- Agents, Anti-Carcinogenic
- Anti Carcinogenic Agents
- Anticarcinogenic Drugs
- Drugs, Anticarcinogenic
Anticarcinogenic Effect- Anticarcinogenic Effect
- Effect, Anticarcinogenic
- Anti-Carcinogenic Effects
- Anti Carcinogenic Effects
- Effects, Anti-Carcinogenic
- Anticarcinogenic Effects
- Effects, Anticarcinogenic
- Anti-Carcinogenic Effect
- Anti Carcinogenic Effect
- Effect, Anti-Carcinogenic
|
Below are MeSH descriptors whose meaning is more general than "Anticarcinogenic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticarcinogenic Agents".
This graph shows the total number of publications written about "Anticarcinogenic Agents" by people in this website by year, and whether "Anticarcinogenic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 1995 | 2 | 0 | 2 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 4 | 0 | 4 | | 2003 | 1 | 2 | 3 | | 2004 | 4 | 1 | 5 | | 2005 | 0 | 2 | 2 | | 2006 | 5 | 0 | 5 | | 2007 | 6 | 1 | 7 | | 2008 | 4 | 0 | 4 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 0 | 2 | | 2011 | 3 | 2 | 5 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 1 | 2 | | 2014 | 2 | 0 | 2 | | 2015 | 3 | 0 | 3 | | 2016 | 2 | 0 | 2 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Anticarcinogenic Agents" by people in Profiles.
-
Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44.
-
New ML, White CM, McGonigle P, McArthur DG, Dwyer-Nield LD, Merrick DT, Keith RL, Tennis MA. Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila). 2018 10; 11(10):643-654.
-
Anderson JC, Baron JA, Ahnen DJ, Barry EL, Bostick RM, Burke CA, Bresalier RS, Church TR, Cole BF, Cruz-Correa M, Kim AS, Mott LA, Sandler RS, Robertson DJ. Factors Associated With Shorter Colonoscopy Surveillance Intervals for Patients With Low-Risk Colorectal Adenomas and Effects on Outcome. Gastroenterology. 2017 06; 152(8):1933-1943.e5.
-
Raina K, Kumar D, Agarwal R. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy. Semin Cancer Biol. 2016 10; 40-41:116-129.
-
Ricciardiello L, Ahnen DJ, Lynch PM. Chemoprevention of hereditary colon cancers: time for new strategies. Nat Rev Gastroenterol Hepatol. 2016 06; 13(6):352-61.
-
Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG, Leggett B, Macrae FA, Ahnen DJ, Casey G, Gallinger S, Haile RW, Le Marchand L, Thibodeau SN, Lindor NM, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst. 2015 Sep; 107(9).
-
Klopper J, Kane M, Jimeno A, Sams S, French J, Pike L, Tompkins K, Haugen B. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. Thyroid. 2015 May; 25(5):563-4.
-
Shrotriya S, Agarwal R, Sclafani RA. A perspective on chemoprevention by resveratrol in head and neck squamous cell carcinoma. Adv Exp Med Biol. 2015; 815:333-48.
-
Ting HJ, Deep G, Jain AK, Cimic A, Sirintrapun J, Romero LM, Cramer SD, Agarwal C, Agarwal R. Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF ß2. Mol Carcinog. 2015 Sep; 54(9):730-41.
-
Ting H, Deep G, Agarwal C, Agarwal R. The strategies to control prostate cancer by chemoprevention approaches. Mutat Res. 2014 Feb; 760:1-15.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|